{"id":"W2083429682","doi":"10.1097/jto.0b013e3181e77a92","title":"Cetuximab as Second-Line Therapy in Patients with Metastatic Esophageal Adenocarcinoma: A Phase II Southwest Oncology Group Study (S0415)","year":2010,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Esophageal Cancer Research and Treatment","field":"Medicine","cited_by":60,"is_retracted":false,"has_abstract":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"National Cancer Institute","keywords":"Medicine; Cetuximab; Internal medicine; Oncology; Phases of clinical research; Regimen; Gastroenterology; Progression-free survival; Epidermal growth factor receptor; Adenocarcinoma; Chemotherapy; Colorectal cancer; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001700661,0.001252908,0.00266064,0.0004983541,0.0003834999,0.001004674,0.0008338999,0.001254548,0.001791997],"category_scores_gemma":[0.0008089141,0.0006345638,0.002119967,0.0006105911,0.0006810773,0.0009290476,0.0003664746,0.002460401,0.0004402249],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001162186,"about_ca_system_score_gemma":0.001808092,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002291384,"about_ca_topic_score_gemma":0.007401448,"domain_scores_codex":[0.9994942,0.0002243868,0.00003284941,0.0001011027,0.00004917629,0.00009819013],"domain_scores_gemma":[0.9993795,0.00008717905,0.0001299988,0.0000529758,0.00003413173,0.0003162903],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.6957706,0.06195768,0.06618558,0.000857097,0.00547923,0.0004469849,0.0004161874,0.005270991,0.04387076,0.0002427597,0.00498324,0.1145189],"study_design_scores_gemma":[0.4816645,0.4034664,0.1030888,0.00006281171,0.002374611,0.0004696623,0.0001419392,0.002359939,0.003619907,0.0001361502,0.002560728,0.00005448934],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9973073,0.001197803,0.0001099913,0.0002255135,0.00005721381,0.0003181886,0.0003863341,0.00002152681,0.0003761698],"genre_scores_gemma":[0.9935105,0.001502058,0.0007512545,0.0008015491,0.0001107083,0.0004461735,0.001869692,0.00001980044,0.00098808],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00266064,"threshold_uncertainty_score":0.008994043,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03023443675054934,"score_gpt":0.4276358738198085,"score_spread":0.3974014370692592,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}